Antipsychotics in MDD Augmentation

CME

Recent Evidence for Treatment Augmentation With Second-Generation Antipsychotics in Major Depressive Disorder

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: May 07, 2020

Expiration: May 06, 2021

Rakesh Jain
Rakesh Jain, MD, MPH

Activity

Progress
1
Course Completed

Treating MDD is challenging. When a patient with MDD does not achieve recovery with antidepressant monotherapy administered at the optimum dose and duration, we can consider adding one of the 4 second-generation antipsychotics approved for augmentation. All have proven efficacy, and all have tolerability challenges, so it is important to tailor the medication choice to individual patients and to use the proper medication dose.

It is also important to offer every patient lifestyle management education and ongoing AE observation and management as they occur. Together, these strategies can greatly improve treatment outcomes for our patients with MDD.